Table 2 Baseline immunisation status in children and adolescents with IBD (N = 69)
From: Immunisation status of children and adolescents with a new diagnosis of inflammatory bowel disease
| Â | n (%) | ||
|---|---|---|---|
Immunisations up to date with routine Australian NIP schedule | 58 (84.1%) | ||
Past history of varicella infection | 10 (14.5%) | ||
Previous vaccination history | |||
 Previous HPV vaccine given (eligible ≥ 12) | 26/44 (59.1%) | ||
 Previous Meningococcal C vaccine givena | 47 (68.1%) | ||
 Previous Influenza vaccine given | 23 (33.3%) | ||
Serologically confirmed immune status (number tested) | |||
 At least 1 serological test | 64/69 (92.8%) | ||
 All 5 serological tests | 52/69 (75.4%) | ||
 HBV immune (60) | 23/60 (38.3%) | ||
 Measles immune (54) | 36/54 (66.7%) Equivocal 2/54 (3.7%) | ||
 Mumps immune (54) | 39/54 (72.2%) Equivocal 3/54 (5.6%) | ||
 Rubella immune (54) | 28/54 (51.9%) Equivocal 7/54 (13.0%) | ||
 VZV immune (62) | 26/62 (41.9%) Equivocal 6/62 (9.7%) | ||
Tuberculosis status | |||
 BCG vaccine | 6 (8.7%) | ||
 Travel to TB high-incident country | 17 (24.6%) | ||
 TB screening at or before SIC | 39 (56.5%) | ||
  QuantiFERON (n = 38) | Negative: 33/38 (86.8%) Indeterminate: 5/38 (13.2%) Positive: 0 | ||
  Tuberculin skin test (n = 1) | Negative: 1 | ||
  QuantiFERON requested but not done | N = 2 | ||
  Patients with travel to high incident country (n = 17) | 15 (88.2%) | p = 0.155 | |
  Patients on biologic agent (n = 16) | 14 (87.5%) | p = 0.009 | |